APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Solid Tumors Drugs

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Solid Tumors Drugs Industry Growth and Trends Forecast to 2032

Report ID 174036790120 December 2025110 pages

Choose your research edition.

Industry ResearchSolid Tumors Drugs Industry Research Report 2026135 pages · $2,950 USDIndustry Growth & TrendsGlobal Solid Tumors Drugs Industry Growth and Trends Forecast to 2032110 pages · $3,450 USDMarket StructureGlobal Solid Tumors Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Solid Tumors Drugs Market Outlook and Growth Opportunities 2026209 pages · $4,250 USDMarket Analysis & ForecastGlobal Solid Tumors Drugs Market Analysis and Forecast 2026-2032206 pages · $4,950 USD

Market perspective

The global Solid Tumors Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Solid Tumors Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Solid Tumors Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Solid Tumors Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Solid Tumors Drugs include Sanofi, Johnson & Johnson, Novartis, Merck, Eli Lilly, Pfizer, GSK, Bayer and AbbVie, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Solid Tumors Drugs market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Solid Tumors Drugs market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Solid Tumors Drugs market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Solid Tumors Drugs.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Solid Tumors Drugs market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Solid Tumors Drugs Market by Company

Sanofi

Johnson & Johnson

Novartis

Merck

Eli Lilly

Pfizer

GSK

Bayer

AbbVie

AstraZeneca

Hoffmann-La Roche

Daiichi Sankyo

Celgene

Boston Biomedical

Boehringer Ingelheim

BMS

Biogen

Solid Tumors Drugs Segment by Type

Small Molecules

Biologics

Solid Tumors Drugs Segment by Application

Academic and Research Institutes

Hospitals

Clinics

Others

Solid Tumors Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Solid Tumors Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Solid Tumors Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Solid Tumors Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Solid Tumors Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Solid Tumors Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Small Molecules Table 2. Major Company of Biologics Table 3. Global Solid Tumors Drugs Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Global Solid Tumors Drugs Sales by Type (2021-2026) & (K Units) Table 5. Global Solid Tumors Drugs Sales Market Share in Volume by Type (2021-2026) Table 6. Global Solid Tumors Drugs Sales by Type (2021-2026) & (US$ Million) Table 7. Global Solid Tumors Drugs Sales Market Share in Value by Type (2021-2026) Table 8. Global Solid Tumors Drugs Price by Type (2021-2026) & (US$/Unit) Table 9. Global Solid Tumors Drugs Sales by Type (2027-2032) & (K Units) Table 10. Global Solid Tumors Drugs Sales Market Share in Volume by Type (2027-2032) Table 11. Global Solid Tumors Drugs Sales by Type (2027-2032) & (US$ Million) Table 12. Global Solid Tumors Drugs Sales Market Share in Value by Type (2027-2032) Table 13. Global Solid Tumors Drugs Price by Type (2027-2032) & (US$/Unit) Table 14. North America Solid Tumors Drugs Sales by Type (2021-2026) & (K Units) Table 15. North America Solid Tumors Drugs Sales by Type (2021-2026) & (US$ Million) Table 16. Europe Solid Tumors Drugs Sales by Type (2021-2026) & (K Units) Table 17. Europe Solid Tumors Drugs Sales by Type (2021-2026) & (US$ Million) Table 18. Asia-Pacific Solid Tumors Drugs Sales by Type (2021-2026) & (K Units) Table 19. Asia-Pacific Solid Tumors Drugs Sales by Type (2021-2026) & (US$ Million) Table 20. Latin America Solid Tumors Drugs Sales by Type (2021-2026) & (K Units) Table 21. Latin America Solid Tumors Drugs Sales by Type (2021-2026) & (US$ Million) Table 22. Middle East and Africa Solid Tumors Drugs Sales by Type (2021-2026) & (K Units) Table 23. Middle East and Africa Solid Tumors Drugs Sales by Type (2021-2026) & (US$ Million) Table 24. Solid Tumors Drugs Industry Trends Table 25. Solid Tumors Drugs Industry Drivers Table 26. Solid Tumors Drugs Industry Opportunities and Challenges Table 27. Solid Tumors Drugs Industry Restraints Table 28. Global Solid Tumors Drugs Sales Revenue by Company (US$ Million) & (2021-2026) Table 29. Global Solid Tumors Drugs Revenue Market Share by Company (2021-2026) Table 30. Global Solid Tumors Drugs Sales by Company (2021-2026) & (K Units) Table 31. Global Solid Tumors Drugs Sales Share by Company (2021-2026) Table 32. Global Solid Tumors Drugs Market Price by Company (2021-2026) & (US$/Unit) Table 33. Global Solid Tumors Drugs Industry Company Ranking, 2024 VS 2025 VS 2026 Table 34. Global Solid Tumors Drugs Major Company Production Sites and Headquarters Table 35. Global Solid Tumors Drugs Company, Product Type & Application Table 36. Global Solid Tumors Drugs Company Establishment Date Table 37. Global Company Market Concentration Ratio (CR5 and HHI) Table 38. Global Solid Tumors Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global Solid Tumors Drugs Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 40. Global Solid Tumors Drugs Sales by Region (2021-2026) & (K Units) Table 41. Global Solid Tumors Drugs Sales Market Share in Volume by Region (2021-2026) Table 42. Global Solid Tumors Drugs Sales by Region (2021-2026) & (US$ Million) Table 43. Global Solid Tumors Drugs Sales Market Share in Value by Region (2021-2026) Table 44. Global Solid Tumors Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 45. Global Solid Tumors Drugs Sales by Region (2027-2032) & (K Units) Table 46. Global Solid Tumors Drugs Sales Market Share in Volume by Region (2027-2032) Table 47. Global Solid Tumors Drugs Sales by Region (2027-2032) & (US$ Million) Table 48. Global Solid Tumors Drugs Sales Market Share in Value by Region (2027-2032) Table 49. Global Solid Tumors Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 50. Global Solid Tumors Drugs Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 51. Global Solid Tumors Drugs Sales by Application (2021-2026) & (K Units) Table 52. Global Solid Tumors Drugs Sales Market Share in Volume by Application (2021-2026) Table 53. Global Solid Tumors Drugs Sales by Application (2021-2026) & (US$ Million) Table 54. Global Solid Tumors Drugs Sales Market Share in Value by Application (2021-2026) Table 55. Global Solid Tumors Drugs Price by Application (2021-2026) & (US$/Unit) Table 56. Global Solid Tumors Drugs Sales by Application (2027-2032) & (K Units) Table 57. Global Solid Tumors Drugs Sales Market Share in Volume by Application (2027-2032) Table 58. Global Solid Tumors Drugs Sales by Application (2027-2032) & (US$ Million) Table 59. Global Solid Tumors Drugs Sales Market Share in Value by Application (2027-2032) Table 60. Global Solid Tumors Drugs Price by Application (2027-2032) & (US$/Unit) Table 61. North America Solid Tumors Drugs Sales by Application (2021-2026) & (K Units) Table 62. North America Solid Tumors Drugs Sales by Application (2021-2026) & (US$ Million) Table 63. Europe Solid Tumors Drugs Sales by Application (2021-2026) & (K Units) Table 64. Europe Solid Tumors Drugs Sales by Application (2021-2026) & (US$ Million) Table 65. Asia-Pacific Solid Tumors Drugs Sales by Application (2021-2026) & (K Units) Table 66. Asia-Pacific Solid Tumors Drugs Sales by Application (2021-2026) & (US$ Million) Table 67. Latin America Solid Tumors Drugs Sales by Application (2021-2026) & (K Units) Table 68. Latin America Solid Tumors Drugs Sales by Application (2021-2026) & (US$ Million) Table 69. Middle East and Africa Solid Tumors Drugs Sales by Application (2021-2026) & (K Units) Table 70. Middle East and Africa Solid Tumors Drugs Sales by Application (2021-2026) & (US$ Million) Table 71. Sanofi Company Information Table 72. Sanofi Business Overview Table 73. Sanofi Solid Tumors Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Sanofi Solid Tumors Drugs Product Portfolio Table 75. Sanofi Recent Development Table 76. Johnson & Johnson Company Information Table 77. Johnson & Johnson Business Overview Table 78. Johnson & Johnson Solid Tumors Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Johnson & Johnson Solid Tumors Drugs Product Portfolio Table 80. Johnson & Johnson Recent Development Table 81. Novartis Company Information Table 82. Novartis Business Overview Table 83. Novartis Solid Tumors Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Novartis Solid Tumors Drugs Product Portfolio Table 85. Novartis Recent Development Table 86. Merck Company Information Table 87. Merck Business Overview Table 88. Merck Solid Tumors Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Merck Solid Tumors Drugs Product Portfolio Table 90. Merck Recent Development Table 91. Eli Lilly Company Information Table 92. Eli Lilly Business Overview Table 93. Eli Lilly Solid Tumors Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Eli Lilly Solid Tumors Drugs Product Portfolio Table 95. Eli Lilly Recent Development Table 96. Pfizer Company Information Table 97. Pfizer Business Overview Table 98. Pfizer Solid Tumors Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Pfizer Solid Tumors Drugs Product Portfolio Table 100. Pfizer Recent Development Table 101. GSK Company Information Table 102. GSK Business Overview Table 103. GSK Solid Tumors Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. GSK Solid Tumors Drugs Product Portfolio Table 105. GSK Recent Development Table 106. Bayer Company Information Table 107. Bayer Business Overview Table 108. Bayer Solid Tumors Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Bayer Solid Tumors Drugs Product Portfolio Table 110. Bayer Recent Development Table 111. AbbVie Company Information Table 112. AbbVie Business Overview Table 113. AbbVie Solid Tumors Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. AbbVie Solid Tumors Drugs Product Portfolio Table 115. AbbVie Recent Development Table 116. AstraZeneca Company Information Table 117. AstraZeneca Business Overview Table 118. AstraZeneca Solid Tumors Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. AstraZeneca Solid Tumors Drugs Product Portfolio Table 120. AstraZeneca Recent Development Table 121. Hoffmann-La Roche Company Information Table 122. Hoffmann-La Roche Business Overview Table 123. Hoffmann-La Roche Solid Tumors Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. Hoffmann-La Roche Solid Tumors Drugs Product Portfolio Table 125. Hoffmann-La Roche Recent Development Table 126. Daiichi Sankyo Company Information Table 127. Daiichi Sankyo Business Overview Table 128. Daiichi Sankyo Solid Tumors Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 129. Daiichi Sankyo Solid Tumors Drugs Product Portfolio Table 130. Daiichi Sankyo Recent Development Table 131. Celgene Company Information Table 132. Celgene Business Overview Table 133. Celgene Solid Tumors Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 134. Celgene Solid Tumors Drugs Product Portfolio Table 135. Celgene Recent Development Table 136. Boston Biomedical Company Information Table 137. Boston Biomedical Business Overview Table 138. Boston Biomedical Solid Tumors Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 139. Boston Biomedical Solid Tumors Drugs Product Portfolio Table 140. Boston Biomedical Recent Development Table 141. Boehringer Ingelheim Company Information Table 142. Boehringer Ingelheim Business Overview Table 143. Boehringer Ingelheim Solid Tumors Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 144. Boehringer Ingelheim Solid Tumors Drugs Product Portfolio Table 145. Boehringer Ingelheim Recent Development Table 146. BMS Company Information Table 147. BMS Business Overview Table 148. BMS Solid Tumors Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 149. BMS Solid Tumors Drugs Product Portfolio Table 150. BMS Recent Development Table 151. Biogen Company Information Table 152. Biogen Business Overview Table 153. Biogen Solid Tumors Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 154. Biogen Solid Tumors Drugs Product Portfolio Table 155. Biogen Recent Development Table 156. North America Solid Tumors Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 157. North America Solid Tumors Drugs Sales by Country (2021-2026) & (K Units) Table 158. North America Solid Tumors Drugs Sales Market Share by Country (2021-2026) Table 159. North America Solid Tumors Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 160. North America Solid Tumors Drugs Sales Market Share Forecast by Country (2027-2032) Table 161. North America Solid Tumors Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 162. North America Solid Tumors Drugs Market Size by Country (2021-2026) & (US$ Million) Table 163. North America Solid Tumors Drugs Market Share by Country (2021-2026) Table 164. North America Solid Tumors Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 165. North America Solid Tumors Drugs Market Share Forecast by Country (2027-2032) Table 166. Europe Solid Tumors Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 167. Europe Solid Tumors Drugs Sales by Country (2021-2026) & (K Units) Table 168. Europe Solid Tumors Drugs Sales Market Share by Country (2021-2026) Table 169. Europe Solid Tumors Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 170. Europe Solid Tumors Drugs Sales Market Share Forecast by Country (2027-2032) Table 171. Europe Solid Tumors Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 172. Europe Solid Tumors Drugs Market Size by Country (2021-2026) & (US$ Million) Table 173. Europe Solid Tumors Drugs Market Share by Country (2021-2026) Table 174. Europe Solid Tumors Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 175. Europe Solid Tumors Drugs Market Share Forecast by Country (2027-2032) Table 176. Asia-Pacific Solid Tumors Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 177. Asia-Pacific Solid Tumors Drugs Sales by Country (2021-2026) & (K Units) Table 178. Asia-Pacific Solid Tumors Drugs Sales Market Share by Country (2021-2026) Table 179. Asia-Pacific Solid Tumors Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 180. Asia-Pacific Solid Tumors Drugs Sales Market Share Forecast by Country (2027-2032) Table 181. Asia-Pacific Solid Tumors Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 182. Asia-Pacific Solid Tumors Drugs Market Size by Country (2021-2026) & (US$ Million) Table 183. Asia-Pacific Solid Tumors Drugs Market Share by Country (2021-2026) Table 184. Asia-Pacific Solid Tumors Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 185. Asia-Pacific Solid Tumors Drugs Market Share Forecast by Country (2027-2032) Table 186. Latin America Solid Tumors Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 187. Latin America Solid Tumors Drugs Sales by Country (2021-2026) & (K Units) Table 188. Latin America Solid Tumors Drugs Sales Market Share by Country (2021-2026) Table 189. Latin America Solid Tumors Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 190. Latin America Solid Tumors Drugs Sales Market Share Forecast by Country (2027-2032) Table 191. Latin America Solid Tumors Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 192. Latin America Solid Tumors Drugs Market Size by Country (2021-2026) & (US$ Million) Table 193. Latin America Solid Tumors Drugs Market Share by Country (2021-2026) Table 194. Latin America Solid Tumors Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 195. Latin America Solid Tumors Drugs Market Share Forecast by Country (2027-2032) Table 196. Middle East and Africa Solid Tumors Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 197. Middle East and Africa Solid Tumors Drugs Sales by Country (2021-2026) & (K Units) Table 198. Middle East and Africa Solid Tumors Drugs Sales Market Share by Country (2021-2026) Table 199. Middle East and Africa Solid Tumors Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 200. Middle East and Africa Solid Tumors Drugs Sales Market Share Forecast by Country (2027-2032) Table 201. Middle East and Africa Solid Tumors Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 202. Middle East and Africa Solid Tumors Drugs Market Size by Country (2021-2026) & (US$ Million) Table 203. Middle East and Africa Solid Tumors Drugs Market Share by Country (2021-2026) Table 204. Middle East and Africa Solid Tumors Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 205. Middle East and Africa Solid Tumors Drugs Market Share Forecast by Country (2027-2032) Table 206. Key Raw Materials Table 207. Raw Materials Key Suppliers Table 208. Solid Tumors Drugs Distributors List Table 209. Solid Tumors Drugs Customers List Table 210. Research Programs/Design for This Report Table 211. Authors List of This Report Table 212. Secondary Sources Table 213. Primary Sources List of Figures Figure 1. Solid Tumors Drugs Image Figure 2. Global Solid Tumors Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Solid Tumors Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Solid Tumors Drugs Sales (2021-2032) & (K Units) Figure 5. Small Molecules Image Figure 6. Global Small Molecules Sales YoY Growth (2021-2032) & (K Units) Figure 7. Biologics Image Figure 8. Global Biologics Sales YoY Growth (2021-2032) & (K Units) Figure 9. Global Solid Tumors Drugs Market Size Overview by Type (2021-2032) & (US$ Million) Figure 10. Global Solid Tumors Drugs Market Share by Type 2025 VS 2032 Figure 11. North America Solid Tumors Drugs Sales Market Share in Volume by Type in 2025 Figure 12. North America Solid Tumors Drugs Sales Market Share in Value by Type in 2025 Figure 13. Europe Solid Tumors Drugs Sales Market Share in Volume by Type in 2025 Figure 14. Europe Solid Tumors Drugs Sales Market Share in Value by Type in 2025 Figure 15. Asia-Pacific Solid Tumors Drugs Sales Market Share in Volume by Type in 2025 Figure 16. Asia-Pacific Solid Tumors Drugs Sales Market Share in Value by Type in 2025 Figure 17. Latin America Solid Tumors Drugs Sales Market Share in Volume by Type in 2025 Figure 18. Latin America Solid Tumors Drugs Sales Market Share in Value by Type in 2025 Figure 19. Middle East and Africa Solid Tumors Drugs Sales Market Share in Volume by Type in 2025 Figure 20. Middle East and Africa Solid Tumors Drugs Sales Market Share in Value by Type in 2025 Figure 21. Global Top 5 and 10 Solid Tumors Drugs Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Academic and Research Institutes Image Figure 24. Global Academic and Research Institutes Sales YoY Growth (2021-2032) & (K Units) Figure 25. Hospitals Image Figure 26. Global Hospitals Sales YoY Growth (2021-2032) & (K Units) Figure 27. Clinics Image Figure 28. Global Clinics Sales YoY Growth (2021-2032) & (K Units) Figure 29. Others Image Figure 30. Global Others Sales YoY Growth (2021-2032) & (K Units) Figure 31. Global Solid Tumors Drugs Market Size Overview by Application (2021-2032) & (US$ Million) Figure 32. Global Solid Tumors Drugs Market Share by Application 2025 VS 2032 Figure 33. North America Solid Tumors Drugs Sales Market Share in Volume by Application in 2025 Figure 34. North America Solid Tumors Drugs Sales Market Share in Value by Application in 2025 Figure 35. Europe Solid Tumors Drugs Sales Market Share in Volume by Application in 2025 Figure 36. Europe Solid Tumors Drugs Sales Market Share in Value by Application in 2025 Figure 37. Asia-Pacific Solid Tumors Drugs Sales Market Share in Volume by Application in 2025 Figure 38. Asia-Pacific Solid Tumors Drugs Sales Market Share in Value by Application in 2025 Figure 39. Latin America Solid Tumors Drugs Sales Market Share in Volume by Application in 2025 Figure 40. Latin America Solid Tumors Drugs Sales Market Share in Value by Application in 2025 Figure 41. Middle East and Africa Solid Tumors Drugs Sales Market Share in Volume by Application in 2025 Figure 42. Middle East and Africa Solid Tumors Drugs Sales Market Share in Value by Application in 2025 Figure 43. North America Solid Tumors Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 44. North America Solid Tumors Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 45. North America Solid Tumors Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 46. North America Solid Tumors Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Solid Tumors Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 48. Europe Solid Tumors Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Solid Tumors Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Europe Solid Tumors Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Solid Tumors Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 52. Asia-Pacific Solid Tumors Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Solid Tumors Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Asia-Pacific Solid Tumors Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Solid Tumors Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 56. Latin America Solid Tumors Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Solid Tumors Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Latin America Solid Tumors Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Solid Tumors Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 60. Middle East and Africa Solid Tumors Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Solid Tumors Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Middle East and Africa Solid Tumors Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Solid Tumors Drugs Value Chain Figure 64. Key Raw Materials Price Figure 65. Manufacturing Cost Structure Figure 66. Solid Tumors Drugs Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Small Molecules
  • Biologics
Applications
  • Academic and Research Institutes
  • Hospitals
  • Clinics
  • Others
Companies covered
  • Sanofi
  • Johnson & Johnson
  • Novartis
  • Merck
  • Eli Lilly
  • Pfizer
  • GSK
  • Bayer
  • AbbVie
  • AstraZeneca
  • Hoffmann-La Roche
  • Daiichi Sankyo
  • Celgene
  • Boston Biomedical
  • Boehringer Ingelheim
  • BMS
  • Biogen

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Solid Tumors Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Solid Tumors Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Solid Tumors Drugs Market by Type
  6. 1.3.1 Small Molecules
  7. 1.3.2 Biologics
  8. 1.4 Global Solid Tumors Drugs Market Size by Type
  9. 1.4.1 Global Solid Tumors Drugs Market Size Overview by Type (2021-2032)
  10. 1.4.2 Global Solid Tumors Drugs Historic Market Size Review by Type (2021-2026)
  11. 1.4.3 Global Solid Tumors Drugs Forecasted Market Size by Type (2027-2032)
  12. 1.5 Key Regions Market Size by Type
  13. 1.5.1 North America Solid Tumors Drugs Sales Breakdown by Type (2021-2026)
  14. 1.5.2 Europe Solid Tumors Drugs Sales Breakdown by Type (2021-2026)
  15. 1.5.3 Asia-Pacific Solid Tumors Drugs Sales Breakdown by Type (2021-2026)
  16. 1.5.4 South America Solid Tumors Drugs Sales Breakdown by Type (2021-2026)
  17. 1.5.5 Middle East and Africa Solid Tumors Drugs Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Solid Tumors Drugs Industry Trends
  2. 2.2 Solid Tumors Drugs Industry Drivers
  3. 2.3 Solid Tumors Drugs Industry Opportunities and Challenges
  4. 2.4 Solid Tumors Drugs Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Solid Tumors Drugs Revenue (2021-2026)
  2. 3.2 Global Top Players by Solid Tumors Drugs Sales (2021-2026)
  3. 3.3 Global Top Players by Solid Tumors Drugs Price (2021-2026)
  4. 3.4 Global Solid Tumors Drugs Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Solid Tumors Drugs Major Company Production Sites & Headquarters
  6. 3.6 Global Solid Tumors Drugs Company, Product Type & Application
  7. 3.7 Global Solid Tumors Drugs Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Solid Tumors Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Solid Tumors Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Solid Tumors Drugs Tier 1, Tier 2, and Tier 3
4 Solid Tumors Drugs Regional Status and Outlook
  1. 4.1 Global Solid Tumors Drugs Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Solid Tumors Drugs Historic Market Size by Region
  3. 4.2.1 Global Solid Tumors Drugs Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Solid Tumors Drugs Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Solid Tumors Drugs Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Solid Tumors Drugs Forecasted Market Size by Region
  7. 4.3.1 Global Solid Tumors Drugs Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Solid Tumors Drugs Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Solid Tumors Drugs Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Solid Tumors Drugs by Application
  1. 5.1 Solid Tumors Drugs Market by Application
  2. 5.1.1 Academic and Research Institutes
  3. 5.1.2 Hospitals
  4. 5.1.3 Clinics
  5. 5.1.4 Others
  6. 5.2 Global Solid Tumors Drugs Market Size by Application
  7. 5.2.1 Global Solid Tumors Drugs Market Size Overview by Application (2021-2032)
  8. 5.2.2 Global Solid Tumors Drugs Historic Market Size Review by Application (2021-2026)
  9. 5.2.3 Global Solid Tumors Drugs Forecasted Market Size by Application (2027-2032)
  10. 5.3 Key Regions Market Size by Application
  11. 5.3.1 North America Solid Tumors Drugs Sales Breakdown by Application (2021-2026)
  12. 5.3.2 Europe Solid Tumors Drugs Sales Breakdown by Application (2021-2026)
  13. 5.3.3 Asia-Pacific Solid Tumors Drugs Sales Breakdown by Application (2021-2026)
  14. 5.3.4 South America Solid Tumors Drugs Sales Breakdown by Application (2021-2026)
  15. 5.3.5 Middle East and Africa Solid Tumors Drugs Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Sanofi
  2. 6.1.1 Sanofi Company Information
  3. 6.1.2 Sanofi Business Overview
  4. 6.1.3 Sanofi Solid Tumors Drugs Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Sanofi Solid Tumors Drugs Product Portfolio
  6. 6.1.5 Sanofi Recent Developments
  7. 6.2 Johnson & Johnson
  8. 6.2.1 Johnson & Johnson Company Information
  9. 6.2.2 Johnson & Johnson Business Overview
  10. 6.2.3 Johnson & Johnson Solid Tumors Drugs Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Johnson & Johnson Solid Tumors Drugs Product Portfolio
  12. 6.2.5 Johnson & Johnson Recent Developments
  13. 6.3 Novartis
  14. 6.3.1 Novartis Company Information
  15. 6.3.2 Novartis Business Overview
  16. 6.3.3 Novartis Solid Tumors Drugs Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Novartis Solid Tumors Drugs Product Portfolio
  18. 6.3.5 Novartis Recent Developments
  19. 6.4 Merck
  20. 6.4.1 Merck Company Information
  21. 6.4.2 Merck Business Overview
  22. 6.4.3 Merck Solid Tumors Drugs Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Merck Solid Tumors Drugs Product Portfolio
  24. 6.4.5 Merck Recent Developments
  25. 6.5 Eli Lilly
  26. 6.5.1 Eli Lilly Company Information
  27. 6.5.2 Eli Lilly Business Overview
  28. 6.5.3 Eli Lilly Solid Tumors Drugs Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Eli Lilly Solid Tumors Drugs Product Portfolio
  30. 6.5.5 Eli Lilly Recent Developments
  31. 6.6 Pfizer
  32. 6.6.1 Pfizer Company Information
  33. 6.6.2 Pfizer Business Overview
  34. 6.6.3 Pfizer Solid Tumors Drugs Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Pfizer Solid Tumors Drugs Product Portfolio
  36. 6.6.5 Pfizer Recent Developments
  37. 6.7 GSK
  38. 6.7.1 GSK Company Information
  39. 6.7.2 GSK Business Overview
  40. 6.7.3 GSK Solid Tumors Drugs Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 GSK Solid Tumors Drugs Product Portfolio
  42. 6.7.5 GSK Recent Developments
  43. 6.8 Bayer
  44. 6.8.1 Bayer Company Information
  45. 6.8.2 Bayer Business Overview
  46. 6.8.3 Bayer Solid Tumors Drugs Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Bayer Solid Tumors Drugs Product Portfolio
  48. 6.8.5 Bayer Recent Developments
  49. 6.9 AbbVie
  50. 6.9.1 AbbVie Company Information
  51. 6.9.2 AbbVie Business Overview
  52. 6.9.3 AbbVie Solid Tumors Drugs Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 AbbVie Solid Tumors Drugs Product Portfolio
  54. 6.9.5 AbbVie Recent Developments
  55. 6.10 AstraZeneca
  56. 6.10.1 AstraZeneca Company Information
  57. 6.10.2 AstraZeneca Business Overview
  58. 6.10.3 AstraZeneca Solid Tumors Drugs Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 AstraZeneca Solid Tumors Drugs Product Portfolio
  60. 6.10.5 AstraZeneca Recent Developments
  61. 6.11 Hoffmann-La Roche
  62. 6.11.1 Hoffmann-La Roche Company Information
  63. 6.11.2 Hoffmann-La Roche Business Overview
  64. 6.11.3 Hoffmann-La Roche Solid Tumors Drugs Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Hoffmann-La Roche Solid Tumors Drugs Product Portfolio
  66. 6.11.5 Hoffmann-La Roche Recent Developments
  67. 6.12 Daiichi Sankyo
  68. 6.12.1 Daiichi Sankyo Company Information
  69. 6.12.2 Daiichi Sankyo Business Overview
  70. 6.12.3 Daiichi Sankyo Solid Tumors Drugs Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Daiichi Sankyo Solid Tumors Drugs Product Portfolio
  72. 6.12.5 Daiichi Sankyo Recent Developments
  73. 6.13 Celgene
  74. 6.13.1 Celgene Company Information
  75. 6.13.2 Celgene Business Overview
  76. 6.13.3 Celgene Solid Tumors Drugs Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Celgene Solid Tumors Drugs Product Portfolio
  78. 6.13.5 Celgene Recent Developments
  79. 6.14 Boston Biomedical
  80. 6.14.1 Boston Biomedical Company Information
  81. 6.14.2 Boston Biomedical Business Overview
  82. 6.14.3 Boston Biomedical Solid Tumors Drugs Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 Boston Biomedical Solid Tumors Drugs Product Portfolio
  84. 6.14.5 Boston Biomedical Recent Developments
  85. 6.15 Boehringer Ingelheim
  86. 6.15.1 Boehringer Ingelheim Company Information
  87. 6.15.2 Boehringer Ingelheim Business Overview
  88. 6.15.3 Boehringer Ingelheim Solid Tumors Drugs Sales, Revenue and Gross Margin (2021-2026)
  89. 6.15.4 Boehringer Ingelheim Solid Tumors Drugs Product Portfolio
  90. 6.15.5 Boehringer Ingelheim Recent Developments
  91. 6.16 BMS
  92. 6.16.1 BMS Company Information
  93. 6.16.2 BMS Business Overview
  94. 6.16.3 BMS Solid Tumors Drugs Sales, Revenue and Gross Margin (2021-2026)
  95. 6.16.4 BMS Solid Tumors Drugs Product Portfolio
  96. 6.16.5 BMS Recent Developments
  97. 6.17 Biogen
  98. 6.17.1 Biogen Company Information
  99. 6.17.2 Biogen Business Overview
  100. 6.17.3 Biogen Solid Tumors Drugs Sales, Revenue and Gross Margin (2021-2026)
  101. 6.17.4 Biogen Solid Tumors Drugs Product Portfolio
  102. 6.17.5 Biogen Recent Developments
7 North America by Country
  1. 7.1 North America Solid Tumors Drugs Sales by Country
  2. 7.1.1 North America Solid Tumors Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Solid Tumors Drugs Sales by Country (2021-2026)
  4. 7.1.3 North America Solid Tumors Drugs Sales Forecast by Country (2027-2032)
  5. 7.2 North America Solid Tumors Drugs Market Size by Country
  6. 7.2.1 North America Solid Tumors Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Solid Tumors Drugs Market Size by Country (2021-2026)
  8. 7.2.3 North America Solid Tumors Drugs Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Solid Tumors Drugs Sales by Country
  2. 8.1.1 Europe Solid Tumors Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Solid Tumors Drugs Sales by Country (2021-2026)
  4. 8.1.3 Europe Solid Tumors Drugs Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Solid Tumors Drugs Market Size by Country
  6. 8.2.1 Europe Solid Tumors Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Solid Tumors Drugs Market Size by Country (2021-2026)
  8. 8.2.3 Europe Solid Tumors Drugs Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Solid Tumors Drugs Sales by Country
  2. 9.1.1 Asia-Pacific Solid Tumors Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Solid Tumors Drugs Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Solid Tumors Drugs Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Solid Tumors Drugs Market Size by Country
  6. 9.2.1 Asia-Pacific Solid Tumors Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Solid Tumors Drugs Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Solid Tumors Drugs Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Solid Tumors Drugs Sales by Country
  2. 10.1.1 South America Solid Tumors Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Solid Tumors Drugs Sales by Country (2021-2026)
  4. 10.1.3 South America Solid Tumors Drugs Sales Forecast by Country (2027-2032)
  5. 10.2 South America Solid Tumors Drugs Market Size by Country
  6. 10.2.1 South America Solid Tumors Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Solid Tumors Drugs Market Size by Country (2021-2026)
  8. 10.2.3 South America Solid Tumors Drugs Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Solid Tumors Drugs Sales by Country
  2. 11.1.1 Middle East and Africa Solid Tumors Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Solid Tumors Drugs Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Solid Tumors Drugs Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Solid Tumors Drugs Market Size by Country
  6. 11.2.1 Middle East and Africa Solid Tumors Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Solid Tumors Drugs Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Solid Tumors Drugs Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Solid Tumors Drugs Value Chain Analysis
  2. 12.1.1 Solid Tumors Drugs Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Solid Tumors Drugs Production Mode & Process
  7. 12.2 Solid Tumors Drugs Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Solid Tumors Drugs Distributors
  10. 12.2.3 Solid Tumors Drugs Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst